This compound, (Z)-Methyl 3-acetamido-4-(2,4,5-trifluorophenyl)but-2-enoate, is primarily utilized as a key intermediate in the synthesis of sitagliptin, an active pharmaceutical ingredient (API) for the treatment of type 2 diabetes. Its unique structure, including the trifluorophenyl group, acetamido moiety, and Z-configuration of the double bond, is essential for the enzymatic activity of the resulting DPP-4 inhibitor, which helps regulate blood glucose levels by enhancing incretin hormone effects. It serves as a valuable building block in medicinal chemistry research for developing drugs targeting metabolic disorders, such as enzyme inhibitors that modulate glucose metabolism. Additionally, its stereochemistry ensures the desired biological activity in the final therapeutic molecule, and it is explored in organic synthesis for constructing complex fluorinated compounds with specific functionalities.